All In Biotech

Drug Trial Radar · NCT04699188

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

344

Actual

Start

Feb 24, 2021

Primary completion

Jan 25, 2027

Study completion Jan 25, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.

Conditions

  • KRAS G12C Mutant Solid Tumors
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Colorectal
  • Cancer of Lung
  • Cancer of the Lung
  • Lung Cancer
  • Neoplasms, Lung
  • Neoplasms, Pulmonary
  • Pulmonary Cancer
  • Pulmonary Neoplasms

Interventions

  • JDQ443Drug

    KRAS G12C inhibitor

  • TNO155Drug

    SHP2 inhibitor

  • tislelizumabBiological

    Anti PD1 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatmentTime frame: 21 days
  2. Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: 24 months
  3. Dose Escalation: Frequency of dose interruptions and reductions, by treatmentTime frame: 24 months
  4. Dose Escalation: Dose intensity by treatmentTime frame: 24 months
  5. Dose Expansion: Overall response rate (ORR) per RECIST v1.1, by treatmentTime frame: 24 months
  6. Dose expansion: Overall intracranial response rate (OIRR) per mRANO-BMTime frame: 24 months
  7. Dose expansion: Incidence and severity of AEs and SAEsTime frame: 24 months
  8. Dose expansion: frequency of dose interruptions and reductions, by treatmentTime frame: 24 months
  9. Dose expansion: Dose intensity by treatmentTime frame: 24 months
  10. Dose expansion: ORR per RECIST 1.1 of JDQ443 single agent in patients with non-small cell lung cancer (JDQ443 dose randomization group only)Time frame: 24 months

Locations

38 sites in 16 countries. Site status is shown where the registry gives one.

  • Emory University School of Medicine-Winship Cancer Institute

    Atlanta, Georgia

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Uni Of TX MD Anderson Cancer Cntr

    Houston, Texas

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Copenhagen, Denmark

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Dresden, Saxony, Germany

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Brescia, BS, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site

    Kashiwa, Chiba, Japan

  • Novartis Investigative Site

    Osaka, Osaka, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site

    Koto Ku, Tokyo, Japan

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Málaga, Spain

  • Novartis Investigative Site

    Valencia, Spain

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.